Waters (WAT) Stock Forecast & Price Target

Waters is supported by a durable replacement cycle in liquid chromatography and mass spectrometry, with aging flow cytometers and installed systems creating years of upgrade demand, while higher-priced platforms like Alliance iS and Xevo MRT should lift ASPs, margins, and recurring reagent, service, and software revenue. The February 2026 BD merger broadens exposure to flow cytometry and microbiology, where switching costs are high, the FDA-cleared BACTEC FXI can refresh an aged ~12,000-instrument base, and management sees roughly $200 million of cost savings by 2027 that could expand operating margins by 170–200 bps. Legacy pharma and manufacturing exposure, including ~15% tied to drug manufacturing and ~60% to pharma, adds a resilient structural tailwind from reshoring and regulated QA/QC workflows, supporting the company’s expected 7%–9% organic constant-currency growth in 2026.

Waters is burdened by a tougher growth profile after the early 2026 merger with Becton Dickinson’s life science and diagnostics business, which added operational complexity, about ~$4B of assumed debt, and exposure to businesses that were previously undermanaged and losing share versus peers. While the core analytical instruments franchise had been executing well, slower-than-expected end-market recovery, competitive pressure, and market saturation could leave organic growth vulnerable just as tougher comps emerge, increasing the risk of multiple compression if the acquired assets underperform. The company’s <5% academic/government exposure limits downside in that end market, but that is offset by constrained capital allocation flexibility, integration risk, and the possibility that the merger permanently dilutes Waters’ organic sales growth potential.